These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 641153)

  • 1. Dominant inheritance of large molecular weight immunoreactive glucagon.
    Palmer JP; Werner PL; Benson JW; Ensinck JW
    J Clin Invest; 1978 Mar; 61(3):763-9. PubMed ID: 641153
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Heterogeneity of plasma glucagon. Circulating components in normal subjects and patients with chronic renal failure.
    Kuku SF; Jaspan JB; Emmanouel DS; Zeidler A; Katz AI; Rubenstein AH
    J Clin Invest; 1976 Sep; 58(3):742-50. PubMed ID: 956399
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Familial hyperglucagonemia--an autosomal dominant disorder.
    Boden G; Owen OE
    N Engl J Med; 1977 Mar; 296(10):534-8. PubMed ID: 189188
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Glucagon immunoreactivities and amino acid profile in plasma of duodenopancreatectomized patients.
    Muller WA; Berger M; Suter P; Cüppers HJ; Reiter J; Wyss T; Berchtold P; Schmidt FH; Assal JP; Renold AE
    J Clin Invest; 1979 May; 63(5):820-7. PubMed ID: 447830
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The role of the liver in glucagon metabolism.
    Jaspan JB; Huen AH; Morley CG; Moossa AR; Rubenstein AH
    J Clin Invest; 1977 Aug; 60(2):421-8. PubMed ID: 874100
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dominant inheritance of large molecular weight species of glucagon.
    Ensinck JW; Palmer JP
    Metabolism; 1976 Nov; 25(11 Suppl 1):1409-11. PubMed ID: 979644
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Excessive circulating large molecular weight immunoreactive glucagon components in subjects with the idiopathic postprandial syndrome.
    Charles MA; Waldeck N
    J Clin Endocrinol Metab; 1981 Aug; 53(2):366-71. PubMed ID: 6265488
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Discrepancy of fasting plasma glucagon levels measured by different glucagon antisera.
    Tahara Y; Tanaka A; Yamamoto Y; Fukuda M; Kumahara Y; Shima K
    Diabetes Res; 1988 Apr; 7(4):179-83. PubMed ID: 3402167
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunoreactive glucagon in nondiabetic and diabetic Macaca nigra.
    Howard CF; Van Bueren A
    Horm Metab Res; 1981 Apr; 13(4):203-6. PubMed ID: 7239433
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Fractional distribution of anti-glucagon immunoreactivity (GIR) and amino acid concentration in the plasma in duodenopancreatectomized patients; preliminary report].
    Muller WA; Berger M; Suter P; Cüppers HJ; Schmidt FH; Wyss T; Assal JP; Loizeau E
    Schweiz Med Wochenschr; 1979 Apr; 109(16):603-4. PubMed ID: 432589
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The role of glucagon deficiency in the Houssay phenomenon of dogs.
    Nakabayashi H; Dobbs RE; Unger RH
    J Clin Invest; 1978 May; 61(5):1355-62. PubMed ID: 659597
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Proglucagon products in plasma of noninsulin-dependent diabetics and nondiabetic controls in the fasting state and after oral glucose and intravenous arginine.
    Orskov C; Jeppesen J; Madsbad S; Holst JJ
    J Clin Invest; 1991 Feb; 87(2):415-23. PubMed ID: 1991827
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hepatic extraction of plasma immunoreactive glucagon components. Predilection for 3500-dalton glucagon metabolism by the liver.
    Jaspan JB; Polonsky KS; Röjdmark S; Ishida T; Field JB; Rubenstein AH
    Diabetes; 1981 Sep; 30(9):767-72. PubMed ID: 7262472
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Glucagon secretion in four duodenopancreatectomized patients after arginine and glucose load.
    Krause U; Thiel M; Beyer J; Mangold G; Cordes U
    Horm Metab Res; 1980 Aug; 12(8):364-9. PubMed ID: 7409739
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vitro and in vivo studies on glucagonoma tissue.
    Berger M; Teuscher A; Halban P; Trimble E; Studer PP; Wollheim CB; Zimmermann-Telschow H; Muller WA
    Horm Metab Res; 1980 Apr; 12(4):144-50. PubMed ID: 6104627
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Possible role of alpha-cell insulin resistance in exaggerated glucagon responses to arginine in type 2 diabetes.
    Tsuchiyama N; Takamura T; Ando H; Sakurai M; Shimizu A; Kato K; Kurita S; Kaneko S
    Diabetes Care; 2007 Oct; 30(10):2583-7. PubMed ID: 17644622
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Glucagon deficiency and hyperaminoacidemia after total pancreatectomy.
    Boden G; Master RW; Rezvani I; Palmer JP; Lobe TE; Owen OE
    J Clin Invest; 1980 Mar; 65(3):706-16. PubMed ID: 6986412
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Secretion by glucagonomas of a possible glucagon precursor.
    Weir GC; Horton ES; Aoki TT; Slovik D; Jaspan J; Rubenstein AH
    J Clin Invest; 1977 Feb; 59(2):325-30. PubMed ID: 833279
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identical biological effects of pancreatic glucagon and a purified moiety of canine gastric immunoreactive glucagon.
    Doi K; Prentki M; Yip C; Muller WA; Jeanrenaud B; Vranic M
    J Clin Invest; 1979 Mar; 63(3):525-31. PubMed ID: 429572
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Size heterogeneity of immunoreactive glucagon during bile-duct obstruction in the rabbit.
    Sanke T
    Endocrinol Jpn; 1982 Oct; 29(5):541-51. PubMed ID: 6763562
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.